The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.
复制标题
整合素结合肽 ATN-161，作为 SARS-CoV-2 感染的新疗法。
DOI：
10.1016/j.jacbts.2020.10.003
复制
发表时间：
2021-01
期刊：
影响因子：
--
通讯作者：
Bix GJ
中科院分区：
文献类型：
--
作者：
Beddingfield BJ;Iwanaga N;Chapagain PP;Zheng W;Roy CJ;Hu TY;Kolls JK;Bix GJ
SARS-CoV-2刺突蛋白与α5β1整合素蛋白和人α5β1结合，便于进入宿主细胞。ATN-161是一种整合素结合肽，它抑制SARS-CoV-2刺突蛋白与其宿主结合伙伴之间的相互作用，通过分子模拟确定了3个结合位点。ATN-161在体外抑制感染，并在预防性给药时显示出细胞活力的增加。ATN-161已经得到了充分的研究，与目前正在进行临床前评估的许多其他化合物相比，有可能更快地进入临床试验。针对目前严重急性呼吸综合征-冠状病毒-2(SARS-CoV-2)大流行的设计和筛选治疗方法的许多努力都集中在通过破坏血管紧张素转换酶-2(ACE2)与SARS-CoV-2刺突蛋白的结合来抑制病毒宿主细胞的进入。这项工作着重于通过假想的基于α5β1整合素−的机制来抑制SARS-CoV-2入侵的可能性，并表明用一种新的分子(ATN-161)抑制尖峰蛋白与α5β1整合素(+/−ACE2)的相互作用以及α5β1整合素与ACE2的相互作用是治疗冠状病毒疾病的一种有前途的方法。
SARS-CoV-2 spike protein binds to α5β1 integrin protein and human ACE2/α5β1, facilitating entry into host cells. ATN-161, an integrin binding peptide, inhibits the interaction between the SARS-CoV-2 spike protein and its host binding partners, with 3 sites of binding identified via molecular modeling. ATN-161 inhibits infection in vitro and demonstrates increases in cell viability when administered prophylactically. ATN-161 is well-studied, with the potential for more rapid introduction into clinical trials than many other compounds currently undergoing preclinical evaluation. Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin−based mechanism and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/− ACE2) and the interaction between α5β1 integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.
登录
查看更多内容
DOI：
10.29271/jcpsp.2020.supp2.s19
发表时间：
2020-06-01
影响因子：
1
作者：
Asgharpour, Masoumeh;Zare, Elham;Alirezaei, Amirhesam
通讯作者：
Alirezaei, Amirhesam
影响因子：
82.9
作者：
Menachery VD;Yount BL Jr;Debbink K;Agnihothram S;Gralinski LE;Plante JA;Graham RL;Scobey T;Ge XY;Donaldson EF;Randell SH;Lanzavecchia A;Marasco WA;Shi ZL;Baric RS
通讯作者：
Baric RS
DOI：
10.1016/j.bbadis.2004.05.005
发表时间：
2004-08-04
影响因子：
6.2
作者：
Lin, QS;Keller, RS;Zisman, LS
通讯作者：
Zisman, LS
影响因子：
3.7
作者：
Clarke NE;Fisher MJ;Porter KE;Lambert DW;Turner AJ
通讯作者：
Turner AJ
影响因子：
6.3
作者：
Edwards, Danielle N.;Salmeron, Kathleen;Bix, Gregory J.
通讯作者：
Bix, Gregory J.